The Bumpy Road To Approving New Alzheimer’s Drugs
In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease. The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Science Friday →
FDA Approves Aducanumab — A Controversial Drug For Alzheimer's
An Alzheimer's uproar
Why There’s More Hope for Alzheimer’s
33%Alzheimer's drug breakthrough, and sugar in space
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.